Genzyme, a Sanofi Company

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Neurology

1100%

R&D Momentum

27/100

Pipeline Velocity

0/100

Trial Completion Rate

50/100

Pipeline Concentration

100/100

Pipeline Freshness

0/100

Activity

Recent Activity

Last 14 days

Sep 10, 2026

Active, not recruiting

A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France

Sep 9, 2026

Completed

ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Earlier

Aug 5, 2026TrialA Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Jul 11, 2026TrialA 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Jun 24, 2026TrialFabry Disease Registry Protocol

Jun 24, 2026TrialPompe Disease Registry

Aug 29, 2025FDAWayrilz — WAYRILZ

Mar 28, 2025FDAQfitlia — QFITLIA

4 more events

Mar 28, 2025FDAQfitlia — QFITLIA

Aug 31, 2022FDAXENPOZYME — XENPOZYME

Feb 6, 2019FDACABLIVI — CABLIVI

Aug 29, 2018FDACerdelga — CERDELGA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

11 patent groups across drugs · Source: FDA Orange Book

DrugExpires

CerdelgaJun 26, 2026 CaprelsaAug 8, 2028 CerdelgaNov 24, 2030 CerdelgaJan 31, 2031 CerdelgaJun 5, 2032 Wayrilz4 patentsMar 1, 2033 Qfitlia2 patentsMar 15, 2033 QfitliaDec 7, 2036

3 more

CerdelgaDec 13, 2038 WayrilzOct 13, 2040 WayrilzFeb 20, 2041

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Neurology

Gaucher Disease Type 1

XENPOZYME

Neurology

Gaucher Disease Type 1

XENPOZYMEPreclinical

Regulatory

Regulatory Timeline

19941 event

FDAMay 23

CEREZYME — CEREZYME

Application BLA020367 (BLA)

19982 events

FDANov 30

THYROGEN — THYROGEN

Application BLA020898 (BLA)

FDAOct 30

Renagel — RENAGEL

Application NDA020926 (NDA)

20001 event

FDAJul 12

Renagel — RENAGEL

Application NDA021179 (NDA)

20011 event

FDAMay 7

Campath — CAMPATH

Application BLA103948 (BLA)

20031 event

FDAApr 30

ALDURAZYME — ALDURAZYME

Application BLA125058 (BLA)

20041 event

FDADec 28

Clolar — CLOLAR

Application NDA021673 (NDA)

20081 event

FDADec 15

Mozobil — MOZOBIL

Application NDA022311 (NDA)

20101 event

FDAMay 24

Lumizyme — LUMIZYME

Application BLA125291 (BLA)

20111 event

FDAApr 6

Caprelsa — CAPRELSA

Application NDA022405 (NDA)

20142 events

FDANov 5

Cerdelga — CERDELGA

Application NDA205494

FDAAug 19

Cerdelga — CERDELGA

Application NDA205494 (NDA)

20151 event

FDAMay 11

Cerdelga — CERDELGA

Application NDA205494

20181 event

FDAAug 29

Cerdelga — CERDELGA

Application NDA205494

20191 event

FDAFeb 6

CABLIVI — CABLIVI

Application BLA761112 (BLA)

20221 event

FDAAug 31

XENPOZYME — XENPOZYME

Application BLA761261 (BLA)

20253 events

FDAAug 29

Wayrilz — WAYRILZ

Application NDA219685 (NDA)

FDAMar 28

Qfitlia — QFITLIA

Application NDA219019 (NDA)

FDAMar 28

Qfitlia — QFITLIA

Application NDA219019

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)